Exposure to proton pump inhibitors and risk of pancreatic cancer. - GreenMedInfo Summary
Exposure to proton pump inhibitors and risk of pancreatic cancer: a meta-analysis.
Expert Opin Drug Saf. 2020 Jan 11. Epub 2020 Jan 11. PMID: 31928106
: To estimate the pooled pancreatic cancer risk among subjects exposed versus not exposed to proton pump inhibitors.: The authors searched PubMed, EMBASE, Scopus, Cochrane Library, and clinicaltrials.gov to identify relevant studies. The authors quantified pancreatic cancer risk among subjects exposed versus not exposed to PPIs, expressed as the pooled (adjusted) odds ratio (OR/aOR) and 95% confidence interval (95%CI) in overall and sensitivity analyses.: One randomized trial, two cohort, four case-control, and five nested case-control studies with 700,178 subjects (73,985 cases; 626,193 controls) were retained. An overall association between PPI exposure and pancreatic cancer risk was observed (OR=1.75, 95%CI=1.12-2.72, I=99%). This was confirmed in sensitivity analyses for high-quality studies, observational studies, case-control studies, studies with pancreatic cancer as the primary outcome, and in sensitivity analyses for diabetes and obesity but not for pancreatitis and smoking. This association was independent of the duration and Defined Daily Dose (DDD) of PPI exposure. In addition to the class effect for PPIs, rabeprazole had a singular significant association with pancreatic cancer (OR=5.40, 95%CI=1.98-14.703, I=87.9%).: The class of PPIs is associated with a 1.75-fold increase in pancreatic cancer risk, confirmed in sensitivity analyses, but was independent of duration, and Defined Daily Dose.